Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for China Pharma Holdings (CPHI) over the last 14 years, with Sep 2025 value amounting to -$122,214.

  • China Pharma Holdings' Cash from Financing Activities fell 1885.97% to -$122,214 in Q3 2025 from the same period last year, while for Sep 2025 it was -$214,633, marking a year-over-year decrease of 521.44%. This contributed to the annual value of $27,353 for FY2024, which is 62.60% down from last year.
  • According to the latest figures from Q3 2025, China Pharma Holdings' Cash from Financing Activities is -$122,214, which was down 318.71% from -$29,188 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Cash from Financing Activities ranged from a high of $4.6 million in Q4 2021 and a low of -$850,555 during Q2 2022.
  • For the 3-year period, China Pharma Holdings' Cash from Financing Activities averaged around -$10,994, with its median value being $6,802 (2024).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 45,928.53% in 2021, then plummeted by 1,885.97% in 2025.
  • Over the past 5 years, China Pharma Holdings' Cash from Financing Activities (Quarterly) stood at $4.6 million in 2021, then plummeted by 114.55% to -$672,063 in 2022, then surged by 104.52% to $30,378 in 2023, then slumped by 77.61% to $6,802 in 2024, then crashed by 1,885.97% to -$122,214 in 2025.
  • Its Cash from Financing Activities stands at -$122,214 for Q3 2025, versus -$29,188 for Q2 2025 and -$70,033 for Q1 2025.